Lumira invests in BAROnova USD$36.5M Series D financing

Lumira invests in BAROnova USD$36.5M Series D financing
November 24
16:06 2015

BAROnova, Inc., has closed a Series D financing of USD$36.5 million.

Delos Capital led the round and Longitude Capital co-led the round, with participation from existing investors Lumira Capital Partners, ONSET Ventures and Sante Ventures.

BAROnova® will use the proceeds to fund the U.S. pivotal study of the TransPyloric Shuttle® (TPS®), BAROnova’s novel endoscopically delivered and retrieved weight-loss device.

The U.S. Food and Drug Administration recently granted BAROnova an unconditional approval to initiate the U.S. pivotal clinical investigation of the TPS, known as the ENDObesity® II Study, which will be used to support a Premarket Approval Application (PMA) with the FDA.

The first subject is expected to be enrolled before the end of 2015.

Press release.

Related Articles

SIGN UP FOR DAILY DEALS AND NEWS UPDATE

CVCA Events

CVCA on Twitter